Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 1000 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and n

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sulfuric acid - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. entrip 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 25 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - magnesium chloride hexahydrate, quantity: 0.1017 g/l; sodium bicarbonate, quantity: 2.94 g/l; sodium chloride, quantity: 6.136 g/l; glucose monohydrate, quantity: 1.1 g/l (equivalent: glucose, qty 1 g/l); calcium chloride dihydrate, quantity: 0.2205 g/l - solution, dialysis - excipient ingredients: carbon dioxide; water for injections; hydrochloric acid; monobasic sodium phosphate dihydrate - replacement fluid, which is administered intravenously in patients with acute renal failure in intensive care units.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - glucose monohydrate, quantity: 1.1 g/l (equivalent: glucose, qty 1 g/l); sodium bicarbonate, quantity: 2.94 g/l; magnesium chloride hexahydrate, quantity: 0.1017 g/l; calcium chloride dihydrate, quantity: 0.2205 g/l; sodium chloride, quantity: 6.136 g/l; potassium chloride, quantity: 0.2982 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; carbon dioxide; monobasic sodium phosphate dihydrate - replacement fluid, which is administered intravenously in patients with acute renal failure in intensive care units.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - tropicamide, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; benzalkonium chloride; purified water; disodium edetate; hydrochloric acid; sodium hydroxide - indications as at 14 july 2003 : used to produce mydriasis and cycloplegia for diagnostic purposes.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - tropicamide, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; sodium hydroxide; disodium edetate; purified water; benzalkonium chloride; hydrochloric acid - indications as at 14 july 2003 : used to produce mydriasis and cycloplegia for diagnostic purposes.